Derived Data from ADNI (Alzheimer’s Disease Neuroimaging Initiative)
Browse by
This collection hosts data generated from processing magnetic resonance (MRI) and positron emission tomography (PET) images from the ADNI Database (adni.loni.usc.edu).
Information about ADNI and access to data from volunteers in North America
Data collection and sharing for ADNI was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Image: Dr Maria del C. Valdés Hernández
Items in this Collection
-
Do 2-year changes in superior frontal gyrus and global brain atrophy affect cognition? Study data
Metabolic alterations to the superior frontal gyrus (SFG) have been linked to cognitive decline and transition from Mild Cognitive Impairment to Alzheimer’s disease (AD). Whether these indicate structural atrophy, which ... -
Complementary information and scripts related to subset of 3 consecutive annual scans from 20 ADNI subjects
This dataset contains the information on the reference images from the ADNI database, used to generate the derived probabilistic maps and white matter hyperintensities binary masks from the subset of 20 subjects scanned ... -
Manual segmentations of white matter hyperintensities from a subset of 7 ADNI subjects scanned three consecutive years, for inter-/intra-observer reliability analyses
This dataset contains structural magnetic resonance imaging (MRI)-derived data from 7 randomly selected participants enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) project. These data are binary masks ... -
Reference segmentations of white matter hyperintensities from a subset of 20 subjects scanned three consecutive years
This dataset contains structural magnetic resonance imaging (MRI)-derived data from 20 participants enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) project. These data are probabilistic estimates maps ... -
SUPERSEDED - Reference segmentations of white matter hyperintensities from a subset of 20 subjects scanned three consecutive years
SUPERSEDED - THIS ITEM HAS BEEN REPLACED BY http://datashare.is.ed.ac.uk/handle/10283/2214. This dataset contains structural magnetic resonance imaging (MRI)-derived data from 20 participants enrolled in the Alzheimer’s ...
RSS 1.0